These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 24324114)

  • 1. Dynamic contrast-enhanced magnetic resonance imaging in the early evaluation of anti-angiogenic therapy in metastatic renal cell carcinoma.
    Panebianco V; Iacovelli R; Barchetti F; Altavilla A; Forte V; Sciarra A; Cortesi E; Catalano C
    Anticancer Res; 2013 Dec; 33(12):5663-6. PubMed ID: 24324114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma.
    Rosen MA; Schnall MD
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):770s-776s. PubMed ID: 17255308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies.
    Antoun S; Lanoy E; Iacovelli R; Albiges-Sauvin L; Loriot Y; Merad-Taoufik M; Fizazi K; di Palma M; Baracos VE; Escudier B
    Cancer; 2013 Sep; 119(18):3377-84. PubMed ID: 23801109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
    Mancuso A; Di Paola ED; Leone A; Catalano A; Calabrò F; Cerbone L; Zivi A; Messina C; Alonso S; Vigna L; Caristo R; Sternberg CN
    BJU Int; 2012 Jan; 109(2):200-6. PubMed ID: 22212284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.
    Seidel C; Busch J; Weikert S; Steffens S; Fenner M; Ganser A; Grünwald V
    Eur J Cancer; 2012 May; 48(7):1023-30. PubMed ID: 22436979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic contrast-enhanced computed tomography as a potential biomarker in patients with metastatic renal cell carcinoma: preliminary results from the Danish Renal Cancer Group Study-1.
    Mains JR; Donskov F; Pedersen EM; Madsen HH; Rasmussen F
    Invest Radiol; 2014 Sep; 49(9):601-7. PubMed ID: 24691140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma.
    de Bazelaire C; Alsop DC; George D; Pedrosa I; Wang Y; Michaelson MD; Rofsky NM
    Clin Cancer Res; 2008 Sep; 14(17):5548-54. PubMed ID: 18765547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma.
    Busch J; Seidel C; Goranova I; Erber B; Peters R; Friedersdorff F; Magheli A; Miller K; Grünwald V; Weikert S
    Eur J Cancer; 2014 Feb; 50(3):563-9. PubMed ID: 24239449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor.
    Grassi P; Verzoni E; Porcu L; Testa I; Iacovelli R; Torri V; Braud Fd; Procopio G
    Future Oncol; 2014 Jun; 10(8):1361-72. PubMed ID: 25052747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma.
    Busch J; Seidel C; Erber B; Issever AS; Hinz S; Kempkensteffen C; Magheli A; Miller K; Grünwald V; Weikert S
    Eur Urol; 2013 Jul; 64(1):62-70. PubMed ID: 22999519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
    Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic contrast-enhanced CT-derived blood flow measurements enable early prediction of long term outcome in metastatic renal cell cancer patients on antiangiogenic treatment.
    Spek A; Graser A; Casuscelli J; Szabados B; Rodler S; Marcon J; Stief C; Staehler M
    Urol Oncol; 2022 Jan; 40(1):13.e1-13.e8. PubMed ID: 34535355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is the pretreatment neutrophil to lymphocyte ratio an important prognostic parameter in patients with metastatic renal cell carcinoma?
    Cetin B; Berk V; Kaplan MA; Afsar B; Tufan G; Ozkan M; Isikdogan A; Benekli M; Coskun U; Buyukberber S
    Clin Genitourin Cancer; 2013 Jun; 11(2):141-8. PubMed ID: 23083797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: feasibility and clinical outcome.
    Sadeghi S; Albiges L; Wood LS; Black SL; Gilligan TD; Dreicer R; Garcia JA; Escudier BJ; Rini BI
    Cancer; 2012 Jul; 118(13):3277-82. PubMed ID: 22139966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy.
    Hittinger M; Staehler M; Schramm N; Ubleis C; Becker C; Reiser M; Berger F
    Urol Oncol; 2012 Sep; 30(5):695-703. PubMed ID: 21865061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy.
    Macfarlane R; Heng DY; Xie W; Knox JJ; McDermott DF; Rini BI; Kollmannsberger C; Choueiri TK
    Cancer; 2012 Jan; 118(2):365-70. PubMed ID: 21717427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small renal masses: assessment of lesion characterization and vascularity on dynamic contrast-enhanced MR imaging with fat suppression.
    Scialpi M; Di Maggio A; Midiri M; Loperfido A; Angelelli G; Rotondo A
    AJR Am J Roentgenol; 2000 Sep; 175(3):751-7. PubMed ID: 10954462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
    Sternberg CN; Hawkins RE; Wagstaff J; Salman P; Mardiak J; Barrios CH; Zarba JJ; Gladkov OA; Lee E; Szczylik C; McCann L; Rubin SD; Chen M; Davis ID
    Eur J Cancer; 2013 Apr; 49(6):1287-96. PubMed ID: 23321547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.
    Motzer RJ; Escudier B; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Figlin RA; Hollaender N; Kay A; Ravaud A;
    Cancer; 2010 Sep; 116(18):4256-65. PubMed ID: 20549832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma.
    Sweis RF; Medved M; Towey S; Karczmar GS; Oto A; Szmulewitz RZ; O'Donnell PH; Fishkin P; Karrison T; Stadler WM
    Clin Genitourin Cancer; 2017 Apr; 15(2):207-212. PubMed ID: 27634566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.